Company intelligence / Profile preview

Symphony Dynamo

USA

Ownership: Private
Development stage: Other

Overview

Symphony Dynamo was a special purpose vehicle created to advance Dynavax's early-stage cancer, hepatitis B, and hepatitis C therapy programs using ISS-based technology. It was established and funded by Symphony Capital Partners, with intellectual property licensed from Dynavax. The agreement allowed Dynavax to focus resources on late-stage programs while keeping options open for Symphony Dynamo's pipeline. Dynavax later acquired Symphony Dynamo, regaining full rights to the programs and technology.

Therapeutic areas: OncologyInfectious Diseases
Modalities: OligonucleotideVaccine
Industry: Biotech

Partnerships

Dynavax TechnologiesRRD International

Beyond the preview

Go deeper on Symphony Dynamo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Symphony Dynamo.

Explore the full profile